Back to search results

Study of 27T51 for Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancers

This study is testing an experimental immune cell therapy called 27T51, which targets a protein called MUC16. It's for adult women with ovarian, primary peritoneal, or fallopian tube cancer that has come back or is hard to treat. Researchers want to see if 27T51, given alone or with cemiplimab and/or bevacizumab, is safe and how well it works. The study will first find the safest dose of 27T51, then test it at that dose, possibly with other medicines. The main goal is to track any side effects over 18 months. You may be able to join if you are 18 or older, have a good performance status (meaning you can do most daily activities), and meet other criteria for your specific cancer type. This study is currently recruiting about 90 participants.

Study design
This is an interventional study with two parts: a dose escalation phase to find the safest dose of 27T51, and a dose expansion phase to test that dose, possibly with other medications. It plans to enroll 90 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for side effects for up to 18 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06469281

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Recruiting
PHASE1Ages 18+InterventionalTreatment
Regeneron Pharmaceuticals
~90 participants
Updated 2026-02-03 on ClinicalTrials.gov
What's tested:27T51CemiplimabBevacizumab

At a glance

Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment emergent adverse events (TEAEs)
Measured over Up to 18 months
+4 more outcomes measured

Conditions

Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer

Explore related trials

Fallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal CarcinomaMUC16 GeneMUC16 wt Allele

Where it's being run

5 sites across 5 states
Massachusetts1
New Jersey1
New York1
Pennsylvania1
Utah1

Study leadership

  • Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals

Who to contact

Clinical Trials Administrator
[email protected]
844-734-6643
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of treatment emergent adverse events (TEAEs)Up to 18 months

    Part 1a

  • Incidence of adverse events of special interest (AESIs)Up to 18 months

    Part 1a

  • Incidence of adverse events of dose limiting toxicities (DLTs)Up to 18 months

    Part 1a

  • Manufacturing feasibility of 27T51Up to 3 years

    Phase 1a/1b Determination of the feasibility of manufacturing 27T51 is measured by the percent of leukapheresis products collected that are able to be manufactured and released for infusion.

  • Overall response rate (ORR) as assessed by the investigatorUp to 48 months

    Phase 1b